NASDAQ · VSTM
Verastem, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VSTM: Nov 05, 2026
Verastem, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.44. The reported EPS for the same quarter last year was $-1.35.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.44 | $-0.43 | $-0.45 | 2 |
| Dec 2026 | $-0.37 | $-0.35 | $-0.39 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · MarketBeat · RTTNews- Zacks · Oct 27, 7:50 AM EDTKiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass EstimatesKiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Oct 23, 6:28 AM EDTVerastem Consensus Price Target Increased by 17.42% to $17.57The average one-year price target for Verastem (NASDAQCM:VSTM) (DB:2VSA) has been revised to $17.57 / share. This is an increase of 17.42% from the prior estimate of $14.96 dated September 29, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not c
- MarketBeat · Oct 14, 12:02 PM EDTVerastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase IIIVerastem (NASDAQ:VSTM) presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. The company also outlined pl
- RTTNews · Oct 14, 7:25 AM EDTVerastem Surges Ahead With VS-7375 Cancer Data, $250M Offering And New CEO Appointment(RTTNews) – Verastem Oncology, Inc. (VSTM), a biopharmaceutical company focused on cancer treatments, reported clinical data showing responses to its investigational KRAS G12D inhibitor VS-7375 across pancreatic, non-small cell lung and colorectal cancers. The company also announ
- RTTNews · Oct 14, 7:07 AM EDTVerastem Oncology Prices $250 Mln Stock, Warrant Offering; Pre-market Shares Up(RTTNews) – Biopharmaceutical company Verastem Oncology (VSTM), announced on Wednesday that it has priced an underwritten offering of 30.94 million shares at $8 each and pre-funded warrants for 0.31 million shares at $7.9999 each, raising about $250 million.
- RTTNews · Oct 14, 7:03 AM EDTVerastem Reports VS-7375 Data, Prices $250M Offering And Names New CEO; Shares Up In Premarket(RTTNews) – Verastem Oncology (VSTM) reported positive responses to its investigational KRAS G12D inhibitor VS-7375 across pancreatic, lung and colorectal cancers in its Phase 1/2 trial. The candidate achieved a 41% response rate in second-line-or-later pancreatic cancer and 43%
- RTTNews · Oct 14, 6:23 AM EDTVerastem Oncology Names Michael Bailey CEO(RTTNews) – Verastem, Inc. (VSTM), a biopharmaceutical company focused on developing and commercializing medicines for cancer treatment, said Wednesday that it has appointed Michael P. Bailey as President and Chief Executive Officer, effective January 1, 2027.
- Zacks · Oct 12, 8:55 AM EDTDoes Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Oct 6, 3:48 AM EDTStrength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- MarketBeat · Sep 21, 11:02 PM EDTVerastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. WainwrightVerastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-737
- Zacks · Sep 8, 10:09 AM EDTVerastem Stock Skyrockets 121% in 3 Months: Here Is WhyVSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
- The Motley Fool · Aug 13, 7:46 PM EDTVerastem (VSTM) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Verastem, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.